Format

Send to

Choose Destination
Case Rep Oncol. 2017 Nov 13;10(3):998-1005. doi: 10.1159/000484041. eCollection 2017 Sep-Dec.

Durable Near-Complete Response to Anti-PD-1 Checkpoint Immunotherapy in a Refractory Malignant Solitary Fibrous Tumor of the Pleura.

Author information

1
WVU Cancer Institute, Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, West Virginia, USA.
2
WVU School of Medicine, West Virginia University, Morgantown, West Virginia, USA.
3
Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA.
4
Department of Pathology, WVU Medicine Ruby Memorial Hospital, West Virginia University, Morgantown, West Virginia, USA.
5
West Virginia Clinical and Translational Science Institute, Morgantown, West Virginia, USA.

Abstract

Solitary fibrous tumor of the pleura is a rare and usually benign primary neoplasm arising from mesenchymal cells of the submesothelial tissue. We present here the case of a patient diagnosed with CD34-positive advanced malignant solitary fibrous tumor of the pleura whose disease failed to respond to combination cytotoxic chemotherapy agents, but demonstrated a prompt near-complete response to checkpoint blockade treatment using the anti-programmed death (PD)-1 monoclonal antibody pembrolizumab, based on tumor molecular profiling revealing tumoral expression positivity for both programmed death-ligand 1 (PD-L1) and PD-1. The patient experienced minimal adverse effects from the treatment with durable favorable response lasting up to cycle 26.

KEYWORDS:

Cancer immunotherapy; Checkpoint blockade; PD-1; PD-L1; Solitary fibrous tumor of the pleura

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland Icon for PubMed Central
Loading ...
Support Center